

DISCOVERY OF NOVEL VIRULENCE MUTANTS BY ASSESSING HYDROGEN  
PEROXIDE SENSITIVITY IN BACILLUS ANTHRACIS

by

Madison R. Rogan

Submitted in partial fulfillment of the  
requirements for Departmental Honors in  
the Department of Biology  
Texas Christian University  
Fort Worth, Texas

May 4, 2015

DISCOVERY OF NOVEL VIRULENCE MUTANTS BY ASSESSING HYDROGEN  
PEROXIDE SENSITIVITY IN BACILLUS ANTHRACIS

Project Approved:

Supervising Professor: Shauna M. McGillivray, Ph.D.

Department of Biology

Giridhar R. Akkaraju, Ph.D.

Department of Biology

Jeffrey Roet, Ph.D.

Department of History & Geography

## ABSTRACT

*Bacillus anthracis*, the causative agent of anthrax and a Disease Category A priority pathogen, utilizes an array of chromosome-encoded virulence factors to subvert the host immune response. After screening a pool of randomly generated *B. anthracis* Sterne mutants, we identified a mutation in the gene *ywIE* that rendered the bacteria more susceptible to hydrogen peroxide than the wild-type. In *Bacillus subtilis*, YwIE plays a role in modulating the stress response (Musumeci *et al.*, 2005). However, experiments confirming this phenotype with an insertional mutant revealed that YwIE does not independently regulate the oxidative stress response in *B. anthracis*. Concurrently, we investigated the larva of the greater wax moth *Galleria mellonella* as a model for *B. anthracis* infection that would be able to provide an *in vivo* demonstration of decreased virulence with the knock-out of YwIE. This organism has shown promising results as an infection model for other human bacterial pathogens, such as *Staphylococcus aureus* (Purves *et al.*, 2010), leading us to test its usefulness in *B. anthracis* studies. We show that while *B. anthracis* Sterne does infect *G. mellonella*, infections with *B. anthracis* Sterne strains of varying degrees of virulence in mammalian models does not correlate with *G. mellonella* survival rates, confirming that this is not an effective model organism for studying *B. anthracis* virulence.

## ACKNOWLEDGMENTS

I would like to thank the College of Science and Engineering Research Center for providing funding for this research. I would also like to thank the friends and family who supported me throughout this project and consistently checked in on the fate of “The Worms”. Finally, I owe my deepest gratitude to my advisor Dr. Shauna McGillivray who has served as a teacher, mentor, and role model for me these past three years.

TABLE OF CONTENTS

INTRODUCTION .....	1
EXPERIMENTAL PROCEDURES.....	5
Bacterial strains and culture conditions .....	5
Generation of YwIE-deficient <i>B. anthracis</i> insertional mutant $\Delta YwIE$ .....	5
Extraction of genomic DNA .....	6
Identification of transposon insertion site.....	7
Hydrogen peroxide survival assays .....	8
<i>Galleria mellonella</i> haemocoelic injections .....	8
RESULTS .....	10
DISCUSSION.....	17
REFERENCES .....	21

## INTRODUCTION

*Bacillus anthracis* is a gram-positive, spore-forming bacteria and the causative agent of anthrax. Infection is most common in domesticated herbivores, but transmission to humans is possible if contact is made with infected animals or contaminated animal products. Cutaneous anthrax is the most common form of the disease and is curable when treated with antibiotics. Inhalational anthrax, resulting from the inhalation of *B. anthracis* endospores and subsequent septicemia, has a mortality rate of greater than 80% (1). The ability of the endospores to rapidly germinate in the macrophage, escape the phagolysosome, and spread to the lymph nodes, circulatory system, and central nervous system are what make *B. anthracis* a Biodefense Category A Priority Pathogen. A push for further investigation of *B. anthracis* pathogenesis followed the 2001 anthrax attacks that infected 22 Americans, killing five (2).

*B. anthracis* virulence is largely attributed to plasmids pX01 and pX02. The precursors of edema toxin and lethal toxin are encoded on pX01 and together make up the anthrax exotoxins. Edema toxin indirectly contributes to virulence by inhibiting function of neutrophils and macrophages and interfering with the inflammatory response (3). The cytolytic properties of lethal toxin target macrophages, increasing levels of IL-1 $\beta$  and inducing septic shock in the host (4). Multiple proteins necessary for the synthesis and regulation of the antiphagocytic capsule are encoded on pX02 (4). Despite the differences in the roles of pathogenesis each plasmid plays, a deficiency in one or both of these virulence plasmids renders the strain nonvirulent in most hosts (4).

While these plasmids are the best-characterized contributors to host disease and death, whole-genome sequencing of fully-virulent *B. anthracis* Ames revealed that the

bacteria possesses multiple chromosome-encoded proteins that are homologous to known virulence factors in the highly related species *Bacillus cereus* and *Bacillus thuringiensis* (5). In order to identify novel chromosome-encoded virulence genes in *B. anthracis*, my mentor Dr. Shauna McGillivray created a library of mutant *B. anthracis* strains via transposon-based mutagenesis (6). This method exposes the bacterial chromosome to short pieces of DNA known as transposons. The transposons possess the ability to insert into the genome in random places, inducing a random mutation each time. Thousands of progeny bacteria are created as a result, each possessing a different mutation caused by the random insertion of a transposon.

Once a library has been created, candidates with mutations in potential virulence genes must be identified through the use of screens that compare the phenotype of the particular mutant strain against wild-type *B. anthracis*. *In vitro* screens mimicking host conditions outside of a live organism can provide the means for quantifying common indicators of virulence and are advantageous because of their ease of use and high throughput nature. For example, hemolytic activity, or lysis of red blood cells, is often an indicator of virulence: not only does it enhance bacterial survival by enabling iron acquisition, but it also indicates general cytolytic abilities. Because anthrax is known to indirectly induce hemolysis (7), measuring the relative *in vitro* hemolytic activity of a particular transposon mutant can indicate genes necessary for this mechanism of disease. Indeed, loss of hemolytic activity *in vitro* was linked to a mutation in the ClpXP ATPase gene of *B. anthracis*, a gene later shown to be essential for virulence in mouse models of infection (6). Additional high throughput *in vitro* screens include assessing proteolytic activity, a *B. anthracis* virulence phenotype caused by numerous caseinolytic and

collagenolytic bacterial proteases (8). *In vivo* models can be useful for initial screening of potential virulence genes, but are limited to invertebrate models such as the nematode *Caenorhabditis elegans* (9). Use of *C. elegans* has identified a collection of possible *B. anthracis* virulence factors. In particular, a cluster of tellurite resistance genes encoded on the *B. anthracis* chromosome was identified as important for resistance to host reactive oxygen species and for full virulence in a mouse model of infection (10).

In this study, we collected a total of 44 transposon mutants that had previously displayed attenuation in one of three screens: proteolysis, hemolysis, and *C. elegans* lethality. To further narrow down this pool of 44 mutants, we applied a hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) survival assay.  $\text{H}_2\text{O}_2$  falls within a class of chemicals known as reactive oxygen species (ROS) which are released by cells of the innate immune system. Without detoxification mechanisms, ROS cause damage to bacterial genetic material, proteins, and lipids (11). Bacteria have evolved ways to subvert the damaging effects of these chemicals by possessing various catabolic pathways for the breakdown of ROS. The purpose of our  $\text{H}_2\text{O}_2$  *in vitro* screen of this mutant library was to identify genes that play more than one role in *B. anthracis* virulence by conferring resistance to  $\text{H}_2\text{O}_2$ .

In addition to investigating ROS susceptibility, we wanted to test the virulence of the mutant library *in vivo*. *In vitro* studies provide a critical preliminary screen necessary for identifying the phenotype in question, but they fail to replicate the same pressures a pathogen would face in a mammalian host. This gap can be remedied through the use of *in vivo* models—vertebrate or invertebrate organisms—that possess innate immune systems which force the pathogen to act similarly to the way it might in a mammalian host. The common laboratory mouse *Mus musculus* and the nematode



*Caenorhabditis elegans*, mentioned above, are infection models that have been used in the past for studying *B. anthracis* virulence. However, *in vivo* models come with their own set of disadvantages. Infection of mice frequently raises ethical and financial concerns that limit their use. *C. elegans* has successfully been used as a model for several pathogens (9) including *B. anthracis* (12), but it requires various manipulations in order for infection to occur which confound its utility as an animal model. Therefore, there is a need for a practical, inexpensive model organism for *B. anthracis* infection.

The larva of the greater waxworm *Galleria mellonella* has shown promising results as an infection model for human bacterial pathogens, such as *Staphylococcus aureus* (13). The larva possesses a well-developed innate immune system, can be infected easily via injection of the pathogen beneath the larva's cuticle (skin), and can incubate at the human body temperature of 37 °C (14), all of which make it a better invertebrate model of infection than the frequently used *C. elegans*. In addition, *G. mellonella* larvae are widely abundant and inexpensive, making them ideal over *M. musculus*. As *G. mellonella* has never before been used to study *B. anthracis*, we wanted to determine its effectiveness as a model organism in the context of bacterial virulence.

My project consists of two major aims: 1) to identify novel genes involved in resistance to oxidative stress; and 2) to assess the effectiveness of *Galleria mellonella* larvae as an infection model with which we can potentially test the virulence of the strains identified in Aim 1 *in vivo*.

## EXPERIMENTAL PROCEDURES

### *Bacterial strains and culture conditions*

*Bacillus anthracis* Sterne strain (pX01<sup>+</sup> pX02<sup>-</sup>) was grown in Brain-Heart-Infusion (BHI) media broth or on agar plates at 37 °C in aerobic conditions.

### *Generation of YwLE-deficient B. anthracis insertional mutant $\Delta YwLE$ .*

Genomic DNA was isolated from *B. anthracis* Sterne using colony PCR (1 colony was added to 10  $\mu$ L of water and microwaved for 1 min) and a 400-base pair region of *ywLE* was amplified by polymerase chain reaction with *ywLE*-specific forward primer (5'-TACAGTGAATTCGGGCACTTGGAATAGGGTTTCACAT-3') containing a site for digestion by restriction enzyme EcoRI and *ywLE*-specific reverse primer (5'-ACTACTG GATCCTTCTGTCATTGTTACTATAATATCTGCCCAATC-3') containing a site for digestion by restriction enzyme BamHI. Temperature-sensitive, erythromycin-resistant plasmid pHY304 and the 400-base pair PCR product were individually digested with EcoRI and BamHI and subsequently ligated together and transformed into electrocompetent *E. coli* strain M1061 (Lucigen). Colonies were grown on BHI + 500  $\mu$ g/mL erythromycin at 30 °C and screened using pHY304-specific forward (5'-ACGAC TCACTATAGGGCGAATTGG-3') and reverse (5'-CCGCTCTAGAACTAGTGGATC CCC-3') primers. The ligated plasmid was then isolated, purified, and transformed into electrocompetent methylation-deficient *E. coli* strain GM2163 because only non-methylated DNA may be transformed into *B. anthracis*. Transformation was selected for and confirmed as described above, and the plasmid was isolated and purified. The plasmid was transformed into electrocompetent *B. anthracis* and grown on BHI + 5

$\mu\text{g/mL}$  erythromycin at 30 °C. Temperature shifting to 37 °C in BHI + 5  $\mu\text{g/mL}$  erythromycin forced integration of plasmid into chromosome. Successful integration was confirmed with pHY304 forward primer and *ywIE*-confirm reverse primer (5'-GATCCG CCAAATGGGTCTG-3').

#### *Extraction of genomic DNA*

12 mL of *B. anthracis* transposon mutant 45F1 grown overnight to stationary phase was pelleted and resuspended in 755  $\mu\text{L}$  of protoplast buffer (20% sucrose, 20 mM Tris-HCl [pH 7.0], 10 mM  $\text{MgCl}_2$ , 0.05% Triton X 100, and double-distilled water to 10 mL). Lysozyme (100 mg/mL) was added to a final concentration of 20 mg/mL and the reaction incubated for one hour at 60 °C. 25  $\mu\text{L}$  of 20% SDS + 10  $\mu\text{L}$  RNase A (10 mg/mL) were added and the reaction incubated for one hour at 37 °C. 10  $\mu\text{L}$  of 20 mg/mL proteinase K was added and the reaction incubated at 50 °C for one hour. An equal volume of phenol/chloroform was added (1 mL) and the mixture was spun for five minutes at 10000 rpm. The upper aqueous layer was removed and set aside. Phenol/chloroform was added again, the mixture was spun, and aqueous layer was once again removed. 3M sodium acetate and isopropanol were added (0.10 and 0.60 volumes, respectively) to aqueous layer containing DNA and reaction was gently mixed until the DNA precipitated. DNA was pelleted by spinning for five minutes at 10000 rpm, washed with 500  $\mu\text{L}$  70% ethanol, and spun again. Ethanol was removed and pellet dried at room temperature for approximately ten minutes. Pellet was resuspended in 100  $\mu\text{L}$  of water.

*Identification of transposon insertion site*

The protocol described by Kwon & Ricke, 2000 was used to identify the sequence flanking the transposon insertion (15). Genomic DNA was extracted from transposon mutant 45F1 using phenol/chloroform as described above and digested with restriction enzyme NlaIII for three hours. 18  $\mu$ L of 100  $\mu$ M “linker 2” (5'-TGTCCTCCGTACATCGT TAGAACTACTCGTACCATCCACAT-3') was phosphorylated with 2  $\mu$ L of PNK, 4  $\mu$ L of 10X T4 ligase buffer (NEB) and 16  $\mu$ L water at 37 °C for one hour, and then heat denatured at 65 °C for 20 minutes. A Y-shaped primer containing an NlaIII digestion site overhang was generated by annealing 18  $\mu$ L of 100  $\mu$ M “linker 1” (5'-TTTCTGCTCGA ATTCAAGCTTCTAACGATGTACGGGGACCATG-3') to heat denatured “linker 2” by heating to 95 °C for five minutes and then allowing the reaction to return slowly to room temperature. Approximately 200 ng of digested DNA was ligated overnight to 5  $\mu$ L of Y-linker with 1  $\mu$ L of T4 DNA ligase (NEB) to a final concentration of 20  $\mu$ L. Reaction was diluted to a final volume of 200  $\mu$ L and the T4 DNA ligase was denatured by heating to 65 °C for ten minutes to denature T4 DNA ligase. 2  $\mu$ L were used for template and amplified with a Y-linker specific primer (5'-CTGCTCGAATTCAAGCTTCT-3') and a transposon-specific primer Himar 1-2 long (5'-GGGAATCATTTGAAGGTT-3') by PCR. The PCR product was gel purified and sequenced with Himar 1-4 primer (5'-TATG CATTTAATACTAGCGAC-3'). The sequenced portion of the genome was identified using a BLAST search.

### *Hydrogen peroxide survival assays*

For the initial hydrogen peroxide screen of 44 *B. anthracis* transposon mutants, bacteria from frozen stocks were grown in static conditions overnight in BHI at 37 °C in a 96-well plate. After 24 hours of growth, bacteria were diluted 1:100 in 200 µL BHI + H<sub>2</sub>O<sub>2</sub> (0%, 0.01%, 0.02%, or 0.04%) and incubated overnight in the same conditions as above. After approximately 24 hours, optical density was measured (600 nm). The data from 3 independent experiments were combined and mutant growth was normalized to WT by calculating the percentage of the optical growth of the mutant at 0.01% H<sub>2</sub>O<sub>2</sub> compared to the optical growth of WT *B. anthracis* at the same concentration. For larger scale assays used to compare the response of WT *B. anthracis* transposon mutant B2 and insertional mutant ΔYwIE, bacteria were grown to log phase in shaking conditions and diluted 1:10 in BHI + H<sub>2</sub>O<sub>2</sub> (0%, 0.005%, 0.0075%, or 0.015%). Optical density (600 nm) was measured after approximately 24 hours. Data represents three independent experiments. Analyses performed included one-way ANOVA followed by Dunnett's post hoc test.

### *Galleria mellonella haemocoelic injections*


The following procedure was modified from Ramarao *et al.*, 2012 (14). *Galleria mellonella* larvae in the last larval stage (during which they no longer feed and begin to produce silk) were ordered from Waxwormstore.com and stored at 4 °C until use. For the *B. anthracis* dilution survival assay, *B. anthracis* Sterne was grown to log phase (optical density [600nm] = 0.4), spun down and resuspended in an equal volume of PBS. Worms were placed at room temperature (about 23 °C) for 24 hours prior to infection. Each

treatment group contained 9-11 waxworms with an average mass of 232 mg. An injection of 20  $\mu\text{L}$  containing  $1.5 \times 10^5$  cfu was administered to the undiluted infection group. The bacteria was diluted ten-fold in PBS and 20  $\mu\text{L}$  containing  $1.4 \times 10^3$  cfu were injected into the 1:10 dilution infection group. Two more ten-fold dilutions were made and 20  $\mu\text{L}$  containing less than 1 cfu (i.e. bacteria undetectable by dilution plating) were injected in to the 1:100 dilution group and 1:1000 dilution group, respectively. Injections were administered by hand with a 1-mL hypodermic syringe through the posterior cuticle (haemocoelic injection). Worms were incubated at 37 °C following infection and survival was recorded at approximately 24 and 48 hours post infection. For the comparison of survival between *B. anthracis* (wild-type and  $\Delta\text{pX01}$ ) and *B. subtilis*, each treatment group contained 10 larvae with an average mass of 145 mg. Larvae were kept at 4 °C until injection was administered to reduce movement. Bacteria strains were grown to log phase. *B. anthracis* WT and  $\Delta\text{pX01}$  were diluted 1:5 in PBS and *B. subtilis* was diluted 1:50 in PBS. Bacteria from each treatment group were enumerated by serial dilution plating. Worms received a total of 10  $\mu\text{L}$  haemocoelic injection administered by an automated pump (New Era Pump Systems NE-500) set to administer 2.5  $\mu\text{L}$  per injection. The WT *B. anthracis* inoculum contained  $5.2 \times 10^4$  cfu, the  $\Delta\text{pX01}$  *B. anthracis* inoculum contained  $2.4 \times 10^4$  cfu, and the WT *B. subtilis* inoculum contained  $3.6 \times 10^4$  cfu. Worms were incubated at 37 °C for 48 hours beginning at time of infection. Survival was recorded at 24 and 48 hours post infection. Data was plotted using a Kaplan-Meier Survival plot.

## RESULTS

*Transposon mutants displaying decreased virulence also show increased susceptibility to hydrogen peroxide.*

Previous work identified 44 *B. anthracis* Sterne transposon mutants that displayed decreased virulence in *in vitro* or *in vivo* virulence screens (6, 9, and data not shown). Of the 44 mutants, 13 displayed increased *C. elegans* survival, 19 displayed low proteolytic activity, and 12 displayed altered hemolytic activity (9 and unpublished data). In order to assess further evidence of decreased virulence, we investigated the ability of the transposon mutants to grow in the presence of hydrogen peroxide. H<sub>2</sub>O<sub>2</sub> is one of several chemicals created by the release of superoxide anions within the macrophage to initiate oxidative stress and subsequent burst in phagocytosed pathogens (10). *B. anthracis*, like many bacterial species, has evolved ways to subvert the consequences of oxidative stress by encoding enzymes such as superoxidase and catalase, which break down these harmful chemicals, and by initiating sporulation within the phagosome for protection (17). We applied a H<sub>2</sub>O<sub>2</sub> survival assay to determine how the transposon mutants might behave in the presence of host ROS. We first determined the minimum inhibitory concentration for growth of WT *B. anthracis* Sterne to be 0.02% H<sub>2</sub>O<sub>2</sub> (data not shown). Mutants were grown overnight to stationary phase and treated with 0.01% H<sub>2</sub>O<sub>2</sub> for approximately 24 hours, after which optical density was measured to determine relative growth (Fig 1). Nine mutants fell below the 35% survival relative to WT growth at the same concentration of H<sub>2</sub>O<sub>2</sub> (Table 1). Of these 9 mutants, the site of the transposon insertion had already been discovered for four. Mutant B11, displaying 17.8% relative growth, possesses a disruption in a tellurium resistance gene and has previously shown



**Figure 1** *B. anthracis* Sterne transposon mutants show varied susceptibility to hydrogen peroxide. WT and transposon mutant *B. anthracis* Sterne grown to stationary phase and treated with 0.01% H<sub>2</sub>O<sub>2</sub>. Optical density was measured after ~24 hours. Data is the combined results of three independent experiments.

ID	Relative survival (%)	Gene disrupted
C7	14.0	Unknown
C5	14.1	Unknown
D6	17.6	Sphingomyelin phosphodiesterase C
C4	17.8	Unknown
B11	17.8	Putative tellurium resistance gene
B2	19.1	Protein tyrosine phosphatase YwIE
C10	22.8	Petrobactin biosynthesis protein AsbC
B6	23.7	Unknown
C6	30.8	Unknown


**Table 1** Transposon mutants demonstrating significant attenuation and their respective mutations. Mutants that fell below a threshold value of 35% growth with regards to WT *B. anthracis* Sterne when treated with 0.01% H<sub>2</sub>O<sub>2</sub> were considered the most attenuated. The location of the transposon insertion was previously identified for about half of the selected mutants. Mutants that underwent further study for reasons described in the text are highlighted.




H<sub>2</sub>O<sub>2</sub> susceptibility (9), further validating our results. Thus, we were able to conclude that several transposon mutants with defects in virulence-associated phenotypes also show evidence of a disruption in their ability to regulate oxidative stress.

*YwIE does not independently affect the resistance of B. anthracis Sterne to hydrogen peroxide.*

We chose to confirm the results seen in transposon mutant B2, which possessed a disruption in the gene coding for low molecular weight protein tyrosine phosphatase YwIE. The role of YwIE has not been investigated in *B. anthracis* but previous studies show its role in facilitating the stress response in *B. subtilis* (18, 19, 20). We created an insertional mutant by targeted insertion of an approximately 4 kbp-plasmid into the gene *ywIE* (Fig 2A). This disruption was confirmed via polymerase chain reaction using a forward primer specific for the plasmid and a reverse primer specific for genomic DNA downstream of the insertion site (Fig 2B). To confirm the results seen with the transposon mutants, we repeated the H<sub>2</sub>O<sub>2</sub> survival assay using WT *B. anthracis* Sterne, the transposon mutant B2, and the insertional mutant  $\Delta$ YwIE. Minimum inhibitory concentration of H<sub>2</sub>O<sub>2</sub> for WT *B. anthracis* Sterne grown to log phase was determined to be 0.01%, due to the lower density of bacterium in the culture (data not shown). WT, transposon mutant, and insertional mutant were grown to log phase and treated with 0.0075% H<sub>2</sub>O<sub>2</sub>. After 24 hours, optical density was measured. WT *B. anthracis* Sterne and the transposon mutant displayed results consistent with the original stationary phase analysis of growth in H<sub>2</sub>O<sub>2</sub>, in that the transposon mutant displayed 11.6% growth;



**Figure 2 Creation of a YwIE insertional mutant.** (A) A 400-base pair region of YwIE was amplified by PCR and inserted into plasmid pHY304. Electrocompetent *B. anthracis* cells were transformed and the plasmid was integrated into the chromosome through homologous recombination. Transformed cells were selected for in 5ug/mL erythromycin + BHI. (B) Successful insertion of the plasmid into the chromosome was screened in two individual colonies by PCR using a pHY304-specific forward primer and a YwIE-specific confirmation reverse primer. Amplified region was detected by gel electrophoresis.



**Figure 3 YwIE is not necessary for the protection of *B. anthracis* against hydrogen peroxide.** Log-phase WT, transposon mutant B2, and insertional mutant  $\Delta$ YwIE *B. anthracis* treated with 0.0075% and 0.015% hydrogen peroxide. Optical density (600nm) measured after ~20 hours. Analyses performed included one-way ANOVA followed by Dunnet's post hoc test. Asterisk indicates  $P < 0.05$ . Data is the combined results of three experiments.

however, the  $\Delta YwIE$  insertional mutant grew comparable to WT *B. anthracis* Sterne (Fig 3). Further investigation using a YwIE complement vector is currently in progress to determine if the transposon mutant possesses another unknown mutation causing the phenotype in question.




**Figure 4 Larvae of the wax moth *G. mellonella*.** *G. mellonella* larvae injected with PBS (left) are still alive and can be easily distinguished from dead worms (right) injected with *B. anthracis*.


*Galleria mellonella* is not an effective model for the study of *B. anthracis* Sterne pathogenesis.

Ramarao *et al.*, 2012 reported on the effectiveness of *Galleria mellonella* larvae for studying the pathogenesis of several bacteria including *Proteus vulgaris* and *Listeria monocytogenes*, and the waxworm has been used to study virulence in *Staphylococcus aureus* (14, 13). We investigated the effectiveness of the worm to serve as an invertebrate model organism for *B. anthracis*

Sterne infection. We found that injection of *B. anthracis* Sterne resulted in a successful infection of the waxworm in comparison to the PBS control (Fig 4). Next, we determined the dose of *B. anthracis* Sterne which would result in 50% lethality to the worms (LD<sub>50</sub>). We administered serial 10-fold dilution of *B. anthracis* Sterne to the waxworms and found that worm survival was dose-dependent and the LD<sub>50</sub> was approximately  $1.4 \times 10^3$  cfu (Fig 5). In order to assess if *G. mellonella* survival can be used as a measure of virulence of a particular strain of *B. anthracis*, we compared the survival rates between a



**Figure 5 *B. anthracis* Sterne kills *G. mellonella* larvae in a dose-dependent manner.** *G. mellonella* larvae received intrahaemocoelic injections of log phase *B. anthracis* Sterne diluted in PBS to the concentrations shown. Injections were administered at 0 hr. Worms incubated at 37°C and percent survival was recorded ~24 and ~48 hours. Each infection group contained 9-11 larvae.



**Figure 6 *G. mellonella* larvae survival rate does not correspond with relative virulence of pathogen.** *G. mellonella* larvae received intrahaemocoelic injections of either WT or anthrax toxin-deficient  $\Delta pX01$  *B. anthracis* Sterne; or non-pathogenic *B. subtilis*. Injections were administered at 0 hr. Worms incubated at 37°C and percent survival was recorded ~24 and ~48 hours. Each infection group contained ten larvae.

WT *B. anthracis* Sterne and a  $\Delta$ pX01 *B. anthracis* Sterne infection group using the LD<sub>50</sub> (Fig 6). *Bacillus subtilis*, a non-pathogenic species, was used as control. Because  $\Delta$ pX01 *B. anthracis* Sterne lacks both virulence plasmids (since the Sterne strain naturally lacks pX02), and produces neither a capsule nor the anthrax toxins, the worms inoculated with that strain should have survival of 100%. After 48 hours, *G. mellonella* survival rates between WT and mutant *B. anthracis* Sterne were comparable—40% survival when treated with WT *B. anthracis* Sterne and 50% survival when treated with the virulence plasmids double-knockout. Among worms inoculated with *B. subtilis* there was 90% survival, indicative of the inability of the bacterium to establish infection. Our results suggest that while *B. anthracis* Sterne can infect *G. mellonella* larvae, the waxworms cannot be used in the context of studying variations in virulence between different strains of the bacteria.

## DISCUSSION

In this study we show that several *B. anthracis* Sterne transposon mutants displaying attenuated virulence-associated phenotypes also show evidence of disruptions in the ability to regulate oxidative stress. We identified a mutation in the gene *ywIE* that rendered the bacteria more susceptible to the reactive oxygen species H<sub>2</sub>O<sub>2</sub> compared to the wild-type. In *Bacillus subtilis* under heat shock conditions, McsB targets CtsR, a repressor for heat shock genes, for degradation by ClpCP protease (19). YwIE works with the ClpC subunit of the protease to inhibit the activation of McsB, thus suppressing the heat shock response in non-stressed cells (20). Therefore, we hypothesized that a disruption in this gene in *B. anthracis* may decrease resistance to certain stresses such as exposure to ROS. However, our attempt to confirm the phenotype seen with the YwIE transposon-induced mutation by the construction of an independent insertional mutant was not successful. It is possible that an unidentified random mutation occurred in the transposon mutant resulting in the phenotype of decreased viability in H<sub>2</sub>O<sub>2</sub>. It is also possible that a second transposon inserted in our mutant in a different location than the one we identified, and it is the unidentified gene contributing to the increased susceptibility rather than *ywIE*. Conversely, our independent insertional mutant may not be disrupting *ywIE* as intended. Follow-up studies in which the transposon mutant  $\Delta YwIE$  is complemented with a YwIE expression vector are underway to distinguish between the phenotypes of transposon mutant  $\Delta YwIE$  and insertional mutant  $\Delta YwIE$ .

As mentioned above, YwIE has been shown to interact with ClpC protease to suppress the heat shock response under normal conditions. Indeed, a double knockout of both YwIE and ClpC in *B. subtilis* saw the most attenuation of growth of the bacteria in

minimal media compared to a single knockout of either YwIE or ClpC (20). In *B. anthracis*,  $\Delta$ ClpC strains display decreased efficiency of sporulation and germination (21), indicating a role for this protease in the stress response of the bacteria. Our studies of the association of YwIE with *B. anthracis* Sterne oxidative stress response could be augmented with investigation of  $\Delta$ ClpC and  $\Delta$ ClpC  $\Delta$ YwIE mutants to assess the combined effect of the two proteins on the viability of *B. anthracis* in H<sub>2</sub>O<sub>2</sub>.

In addition to the transposon disruption associated with YwIE, we identified eight other H<sub>2</sub>O<sub>2</sub>-sensitive mutants. Interestingly one of these strains possessing a mutation in a tellurium resistance gene has already been published as displaying increased susceptibility to H<sub>2</sub>O<sub>2</sub> (9). We selected a second mutant, C5, whose mutation was unknown and attempted to identify the location of the transposon insertion. This particular strain displayed 14.1% growth in H<sub>2</sub>O<sub>2</sub> relative to WT *B. anthracis* Sterne (Fig 1). However, efforts to sequence the amplified region were unsuccessful (data not shown). Future studies will follow up with C5 and the other eight mutants to determine their site of disruption and to confirm the genotype/phenotype association. Ultimately, we hope to continue to elucidate novel *B. anthracis* protection mechanisms against host innate immune defense such as reactive oxygen species.

In addition to using *in vitro* models of infection, such as the H<sub>2</sub>O<sub>2</sub> assay, our lab is interested in using *in vivo* models to test how the presence or absence of a particular chromosome-encoded virulence factor affects the infectivity of *B. anthracis* Sterne. To do so, a relatively inexpensive and easily available model of infection must be developed. Invertebrate models are ideal because they are abundant, possess innate immune systems, and can be easily utilized for the purpose of high throughput screening. We investigated

the ability of the waxworm *G. mellonella* to be used as an invertebrate model organism for *B. anthracis*. We found that *B. anthracis* Sterne can infect *G. mellonella* larvae and does so in a dose-dependent manner. However, we also wanted to use *G. mellonella* as an *in vivo* model for identifying novel virulence factors. Unfortunately we saw no apparent difference in the survival rates of waxworms infected with WT *B. anthracis* Sterne and  $\Delta pX01$ , a strain of *B. anthracis* lacking both virulence plasmids and thus unable to establish infection in most hosts. This finding renders the worms useless for our lab's purposes. This was unexpected as differences in virulence correlating to the absence of one virulence factor in studies of *S. aureus*-infected waxworms was reflected in waxworm survival (13). It is still possible, however, to use the worms in studies of antimicrobial effectiveness. For example, investigations into strains of *B. anthracis* that display increased antibiotic sensitivity could be supplemented with the inclusion of a *G. mellonella* infection model to which antibiotics are administered and survival is assessed.

The identification and definition of *B. anthracis* virulence factors have many implications for human health. It allows for a broadening of the understanding of the host-pathogen interaction, which equips scientists to better prevent and treat infection of not only *B. anthracis* but also other clinically relevant pathogens such as methicillin-resistant *Staphylococcus aureus*, or MRSA. With the spread of antibiotic resistant bacteria, knowledge of a pathogen's virulence factors is necessary for the development of anti-virulence factor therapy, an antibacterial treatment that targets the very component needed by a pathogen to establish infection (16). Using a drug to cripple one of the factors utilized by pathogen to invade a host results in better clearance of the bacteria by the host immune system. Anti-virulence factor therapy has several advantages over



antibiotics including a high degree of specificity which decreases side effects, and the absence of a strong selection pressure which discourages the development of drug resistance (16). As antibiotic resistance spreads, understanding what comprises a pathogen's disease-causing arsenal will be an important area of study for the development of different modes of antibacterial therapy.

## REFERENCES

1. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. *NEJB* **341**, 815-26 (1999).
2. Guarner J, Jernigan JA, Shieh W, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR, & Inhalational Anthrax Pathology Working Group. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. *The Am J of Pathol* **163**, 701-09 (2003).
3. Okinaka RT, Cloud K, Hampton O, Hoffmaster AR, Hill KK, Keim P, Koehler TM, Lamke G, Kumano S, Mahillon J, Manter D, Martinez Y, Ricke D, Svensson R, & Jackson PJ. Sequence and organization of pXO1, the large *Bacillus anthracis* plasmid harboring the anthrax toxin genes. *J of Bacteriol* **181**, 6509-15 (1999).
4. Little SF & Ivins BE. Molecular pathogenesis of *Bacillus anthracis* infection. *Micobes and Infect* **2**, 131-39 (1999).
5. Read TD, Peterson SN, Tourasse N, Baillie LW, Paulsen IT, Nelson KE, Tettelin H, Fouts DE, Eisen JA, Gill SR, Holtzapple EK, Okstad OA, Helgason E, Rilstone J, Wu M, Kolonay JF, Beanan MJ, Dodson RJ, Brinkac LM, Gwinn M, DeBoy RT, Madpu R, Daugherty SC, Durkin AS, Haft DH, Nelson WC, Peterson JD, Pop M, Khouri HM, Radune D, Benton JL, Mahamoud Y, Jiang L, Hance IR, Weidman JF, Berry KJ, Plaut RD, Wolf AM, Watkins KL, Nierman WC, Hazen A, Cline R, Redmond C, Thwaite JE, White O, Salzberg SL, Thomason B, Friedlander AM, Koehler TM, Hanna PC, Kolstø AB, & Fraser CM. The genome sequence of *Bacillus anthracis* Ames and comparison to closely related bacteria. *Nature* **423**, 81–86 (2003).

6. McGillivray SM, Ebrahimi CM, Fisher N, Sabet M, Zhang DX, Chen Y, Haste NM, Aroian RV, Gallo RL, Guiney DG, Friedlander AM, Koehler TM, & Nizet V. ClpX contributes to innate defense peptide resistance and virulence phenotypes of *Bacillus anthracis*. *J of Innate Imm* **1**, 494-506 (2009).
7. Wu AG, Alibek D, Li YL, Bradburne C, Bailey CL, & Alibek K. Anthrax toxin induces hemolysis: an indirect effect through polymorphonuclear cells. *J Infect Dis* **188**, 1138-41 (2003).
8. Popov SG, Popova TG, Hopkins S, Weinstein RS, MacAfee R, Fryxell KJ, Chandhoke V, Bailey C, & Alibek K. Effective antiprotease-antibiotic treatment of experimental anthrax. *BMC Infect Dis* **5** (2005). Doi: 10.1186/1471-2334-5-25
9. Franks SE, Ebrahimi C, Hollands A, Okumura CY, Aroian RV, Nizet V, & McGillivray SM. Novel role for the yceGH tellurite resistance genes in the pathogenesis of *Bacillus anthracis*. *Infect and Immun* **82**, 1132–40 (2014).
10. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. *Nat Rev Micro* **2**, 820–32 (2004).
11. Sifri C, Begun J, & Ausubel FM. The worm has turned – microbial virulence modeled in *Caenorhabditis elegans*. *Trends in Micro* **13**, 119-27 (2005).
12. Kho MF, Bellier A, Balasubramani V, Hu Y, Hsu W, Nielsen-LeRoux C, McGillivray SM, Nizet V, & Aroian RV. The pore-forming protein Cry5B elicits the pathogenicity of *Bacillus* sp. against *Caenorhabditis elegans*. *PLoS ONE* **6**, e29122 (2011).
13. Purves J, Cockayne A, Moody PCE, & Morrissey JA. Comparison of the regulation, metabolic functions, and roles in virulence of the glyceraldehyde-3-

phosphate dehydrogenase homologues gapA and gapB in *Staphylococcus aureus*. *Infect and Immun* **78**, 5223–32 (2010).

14. Ramarao N, Nielsen-LeRoux C, & Lereclus D. The insect *Galleria mellonella* as a powerful infection model to investigate bacterial pathogenesis. *J Vis Exp* **70**, e4392 (2012).
15. Kwon YM & Ricke SC. Efficient amplification of multiple transposon-flanking sequences. *J of Micro Methods* **41**, 195–99 (2000).
16. Clatworthy AE, Pierson E, & Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* **3**, 541–48 (2007).
17. Kim SH, Kim SK, Jung KH, Kim YK, Hwang HC, Ryu SG, & Chai YG. Proteomic analysis of the oxidative stress response induced by low-dose hydrogen peroxide in *Bacillus anthracis*. *J Microbiol Biotechnol* **23**, 750-58 (2013).
18. Musumeci L, Bongiorno C, Tautz L, Edwards RA, Osterman A, Perego M, Mustelin T, & Bottini N. Low-molecular-weight protein tyrosine phosphatases of *Bacillus subtilis*. *J of Bacteriol* **187**, 4945-56 (2005).
19. Elsholz AKW, Michalik S, Zühlke D, Hecker M, & Gerth U. CtsR, the Gram-positive master regulator of protein quality control, feels the heat. *The EMBO Journal* **29**, 3621-29 (2010).
20. Elsholz AKW, Hempel K, Michalik S, Gronau K, Becher D, Hecker M, & Gerth U. Activity control of the ClpC adaptor McsB in *Bacillus subtilis*. *J of Bacteriol* **193**, 3887-93 (2011).
21. Singh LK, Dhasmaria N, Sajid A, Kumar P, Bhaduri A, Bharadwaj, Gandotra S, Kalia VC, Das TK, Goel AK, Pomerantsev AP, Misra R, Gerth U, Leppia SH, &

Sing Y. ClpC operon regulates cell architecture and sporulation in *Bacillus anthracis*. *Environ Microbiol* **17**, 855–65 (2015).